Melar Acquisition Corp. I (MACIU) Prices $150M IPO
by Nicholas Alan Clayton on 2024-06-17 at 7:50pm

Melar Acquisition Corp. I announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “MACIU”, Tuesday, June 18, 2024.

The new SPAC aims to combine with a company in retail finance, specialty finance or financial technology specifically targeted at helping small businesses transact payments and make sustainable investments.

Melar I’s sponsor team will be led by CEO and Chairman Gautam Ivatury, CFO Edward Lifshitz and COO Eric Lifshitz. Dan Rosen, Ken Ruggiero and Tara Kenney are to serve as Board Directors.

Total SPAC deal count for 2024 year-to-date is now 14. This offering is expected to close on Thursday, June 20, 2024.


Cohen & Company Capital Markets is acting as lead book-running manager with Seaport Global Securities acting as joint book runner for the offering. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Morgan Lewis & Bockius LLP serving as Underwriter’s Counsel. WithumSmith+Brown serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.

Recent Posts
by Kristi Marvin on 2024-10-26 at 10:00am

Terms Tracker for the Week Ending October 25, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Finally, a little more SPAC action this week with no less than four IPOs priced.  That brings October’s tally to seven IPOs with one more...

by Nicholas Alan Clayton on 2024-10-25 at 8:15am

At the SPAC of Dawn The rebound of the growth companies that made up the SPAC class of 2021 has been one of the bigger stories of second half of 2024, but not all of the de-SPACs are feeling the love equally. Instead, in many new sectors that hit the public markets together as a...

by Nicholas Alan Clayton on 2024-10-24 at 11:54am

DT Cloud (NASDAQ:DYCQ) has entered into a definitive agreement to combine with Maius Pharmaceutical at an equity value of $250 million. Shanghai-based Maius is a drug developer and researcher focused on small-molecule chemical treatments for different forms of cancer. The combined company is expected to trade on the Nasdaq once the deal is completed in...

by Nicholas Alan Clayton on 2024-10-24 at 10:18am

Charlton Aria Acquisition Corporation announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CHARU”, Thursday, October 24, 2024. The new SPAC plans to focus on industries that complement the management team’s and board of director’s background and network. The sponsor team for...

by Nicholas Alan Clayton on 2024-10-24 at 8:30am

At the SPAC of Dawn As the market goes through a cooling period this week, new readouts for jobless claims and new home sales are set to hit later today. Jobless claims are of course something of a proxy indicator for SPACs as to when the Fed might continue to its rate-cutting process, while home...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved